Piper Sandler Maintains Overweight on Biomea Fusion, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on Biomea Fusion (NASDAQ:BMEA) but lowers the price target from $45 to $10.

June 07, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains an Overweight rating on Biomea Fusion but significantly lowers the price target from $45 to $10, indicating a more cautious outlook.
The significant reduction in the price target from $45 to $10 suggests a more cautious outlook on Biomea Fusion's future performance, which is likely to negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100